Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:TH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on Oct 25, 2024 10:22am
RE:Anyone at Jubilant
Like always keeping the suspense alive. Anyone else lost some sleep since December 2022.
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Post by
Trogarzon
on Oct 24, 2024 8:04pm
Anyone at Jubilant
Anyone know if Jubilant made an Egrifta batch on October 21...
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Post by
Trogarzon
on Oct 23, 2024 7:06am
October 21st
Wonder if they confirm the new batch of Egrifta was made on the 21st. It would be advisable to do so asap. Also the subsequent filing and probable timeline for fda public servants to do their
...more
(107)
•••
Trogarzon
X
View Profile
View Bullboard History
Post by
Trogarzon
on Oct 22, 2024 8:15pm
The Research capital upgrade details
https://www.cantechletter.com/2024/10/thtx-upgraded-at-research-capital/amp/ Starts by stating that the Egrifta shortage is in the rear view mirror, then states that it's not fixed yet, then
...more
(54)
•••
PWIB123
X
View Profile
View Bullboard History
Comment by
PWIB123
on Oct 21, 2024 10:52am
RE:RE:Research capital
Appreciate you sharing this. Every little positive step forward is critical at this juncture.
(1025)
•••
Maxmoe
X
View Profile
View Bullboard History
Comment by
Maxmoe
on Oct 21, 2024 10:17am
RE:Research capital
Without reprinting the whole report, I can summarize andre's view as extremely cautious, but extremely optimistic. That's an upgrade from extremely uncertain and no buy rating. $3.80 USD
...more
(1025)
•••
Maxmoe
X
View Profile
View Bullboard History
Post by
Maxmoe
on Oct 21, 2024 9:52am
Research capital
We are upgrading THTX to a Speculative Buy Rating with a Target Price of $3.80 (all nos in US$).
(197)
•••
scarlet1967
X
View Profile
View Bullboard History
Comment by
scarlet1967
on Oct 19, 2024 5:57pm
RE:RE:World ADC 2024
One can be cautiously optimistic not only because of the language used but the fact that CMO published recently an article posted earlier here and attending various conferences, getting interviewed..
(56)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on Oct 19, 2024 5:21pm
RE:World ADC 2024
Here's a step-by-step analysis: 1. Context of the Field ADCs have revolutionized cancer treatment by using antibodies to deliver toxic drugs specifically to cancer cells. This
...more
(40)
•••
Lee430
X
View Profile
View Bullboard History
Comment by
Lee430
on Oct 19, 2024 5:06pm
RE:World ADC 2024
Scarlet, reading between the lines of this quote you highlighted would one dare to infer that the trial is going well? "We are still working to optimize the dose, but the trial program has
...more
(197)
•••
scarlet1967
X
View Profile
View Bullboard History
Post by
scarlet1967
on Oct 19, 2024 10:26am
World ADC 2024
https://web.hansonwadegroup.com/rs/355-DOS-429/images/World_ADC_San_Diego_2024_Speaker_Interview_Theratechnologies.pdf?utm_source=digital&utm_medium=social-post&utm_campaign=content&utm
...more
(1025)
•••
Maxmoe
X
View Profile
View Bullboard History
Post by
Maxmoe
on Oct 18, 2024 2:12pm
Newsflash?
Being fat is bad? Thanks man. What's next? Being old? I'm doomed. Thank goodness no hiv. But with TH stock bouncing back, I can afford to enjoy my old age and ill health in the lap of luxury.&
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 17, 2024 2:00pm
New Press Release - Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Data Show Tesamorelin May Reduce CVD Risk by Reducing EVAF MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on development and commercialization of innovative therapies, today...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 17, 2024 7:30am
New Press Release - Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Baseline Data Show More Frequent Selection of Ibalizumab in Patients with Lower CD4 Counts and Higher Viral Loads, Compared to Other Regimens MONTREAL, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical...
read article.
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >